|Despite the number of approved treatment options, the management of diabetic eye disease remains challenging. In clinical trials for all the approved agents, more than half of the patients have not achieved improvements of 3 lines on initial therapy. The underlying disease process affects a patient’s risk for developing glaucoma, and treatment with steroids can further elevate IOP. In this activity, leading clinicians will discuss the benefits and limitations of available treatment options, strategies for moving beyond first-line therapy that is not effective, the potential for combination therapy, and how to manage glaucoma in patients with diabetic eye disease. The use of cases will allow attendees to compare their approaches to those of the faculty in this interactive activity.